The treatment of myelodysplastic syndromes (MDSs) continues to be challenging and difficult to standardize. This article describes a decision tree for the treatment of MDSs based on age, presence or absence of a potential HLA-identical donor, and prognostic factors including bone marrow blast proportion, severity of cytopenias, and karyotype.